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Abstract: Pseudoachondroplasia (PSACH), a short limb skeletal dysplasia associated with premature
joint degeneration, is caused by misfolding mutations in cartilage oligomeric matrix protein (COMP).
Here, we define mutant-COMP-induced stress mechanisms that occur in articular chondrocytes of MT-
COMP mice, a murine model of PSACH. The accumulation of mutant-COMP in the ER occurred early
in MT-COMP articular chondrocytes and stimulated inflammation (TNFα) at 4 weeks, and articular
chondrocyte death increased at 8 weeks while ER stress through CHOP was elevated by 12 weeks.
Importantly, blockage of autophagy (pS6), the major mechanism that clears the ER, sustained cellular
stress in MT-COMP articular chondrocytes. Degeneration of MT-COMP articular cartilage was
similar to that observed in PSACH and was associated with increased MMPs, a family of degradative
enzymes. Moreover, chronic cellular stresses stimulated senescence. Senescence-associated secretory
phenotype (SASP) may play a role in generating and propagating a pro-degradative environment in
the MT-COMP murine joint. The loss of CHOP or resveratrol treatment from birth preserved joint
health in MT-COMP mice. Taken together, these results indicate that ER stress/CHOP signaling
and autophagy blockage are central to mutant-COMP joint degeneration, and MT-COMP mice joint
health can be preserved by decreasing articular chondrocyte stress. Future joint sparing therapeutics
for PSACH may include resveratrol.
Keywords: cartilage oligomeric matrix protein; pseudoachondroplasia; autophagy; ER stress;
dwarfism; chondrocyte; articular cartilage; joint degeneration
1. Introduction
Cartilage oligomeric matrix protein (COMP) is a large, matricellular protein that medi-
ates a variety of cell–cell and cell–matrix interactions [1–7]. COMP interacts with many ex-
tracellular matrix (ECM) proteins, including, but not limited to, collagens types I, II, IX, XII,
XIV, matrilin-3, aggrecan, and fibronectin [8–12] and may provide a hub for interaction(s)
of collagens with proteoglycans and other ECM proteins [8,9,11]. COMP likely plays a role
in the mechanical strength of ECM tissues, as loading increases COMP levels in tendons
and aging or overuse decreases abundance [11,13]. Chondrocyte proliferation and chondro-
genesis is stimulated by COMP [14,15]. Mutations in COMP cause pseudoachondroplasia
(PSACH), a severe dwarfing condition characterized by disproportionate short stature,
short limbs, joint laxity, pain, and early onset joint degeneration [2,9,16–38]. PSACH birth
parameters are normal, and the first sign of the disorder is decelerating linear growth, start-
ing by the end of the first year, and a waddling gait developing by two years of age [29,32].
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Radiographic examination leads to a diagnosis, and the key characteristics are shortening
of all the long bones; small abnormal epiphyses; widened and irregular metaphyses; small,
underossified capital femoral epiphyses; and platyspondyly [21,29,32,36,37]. While loss
of linear growth is the most obvious untoward outcome in PSACH, joint dysfunction and
pain are the most debilitating and long-term complications. Pain is significant and begins
in childhood, likely from the inflammation, which plays a role in the underlying growth
plate chondrocyte pathology [17,21,34,39,40], whereas the pain in adulthood may reflect
joint degenerative changes that necessitate hip replacement in a majority of adults [29].
Joint degeneration in PSACH occurs very early in life between the second or third decades,
and all joints are affected, especially the hips, elbows, and shoulders [29,37,41,42].
Long before COMP mutations were identified as the cause of PSACH, it was known
that growth plate chondrocytes contained massive amounts of material in the rER cister-
nae. Later studies proved that mutant-COMP does not fold properly and, therefore, is
retained in the ER [19,39]. Moreover, mutant-COMP prematurely interacts with bind-
ing partners in the ER, forming an ordered matrix composed of types II and IX col-
lagen, matrilin 3 (MATN3), and other ECM proteins, resulting in intracellular protein
accumulation [30,31,40]. This material is not degraded efficiently enough to maintain
chondrocyte function and fills the cytoplasmic space, becoming toxic to growth plate chon-
drocytes [2,21,33,35]. To study the cellular mechanism involved in the PSACH pathology, a
doxycycline (DOX)-inducible mouse that expresses mutant-D469del-COMP (designated the
MT-COMP mouse) in chondrocytes was generated [40]. The MT-COMP mouse mimics the
clinical phenotype and chondrocyte PSACH pathology [40–43]. Studies of the MT-COMP
mouse showed that mutant-COMP is retained in the rER of growth plate chondrocytes,
stimulating ER stress through the CHOP pathway that in turn activates oxidative and
inflammatory processes, initiating a self-perpetuating stress loop involving oxidative stress
and inflammation. This stress loop leads to DNA damage, necroptosis, and loss of growth
plate chondrocytes [43–45]. ER stress and TNFα-driven inflammation increase mTORC1
signaling [42], which represses autophagy, eliminating a critical mechanism needed to
clear misfolded proteins and results in intracellular accumulation in growth plate chondro-
cytes [42]. This molecular mechanistic process explains the deceleration in linear growth
associated with PSACH.
In this work, we focused on delineating the effect of mutant-COMP on joint health in
our PSACH mouse model and the timing of joint degeneration. Articular and growth plate
cartilages serve very different functions, and these tissues mature at different times [46,47].
Growth plate chondrocytes generate a large volume of matrix, driving long-bone growth
and, after reaching hypertrophy, chondrocytes die. In contrast, articular chondrocytes syn-
thesize matrix to provide lubrication and a cushion to withstand compressive forces during
movement, and they are very long lived. Growth is essential to both fetal and postnatal
periods, while withstanding weight bearing compressive forces during ambulation occur
postnatally. Both articular and growth plate chondrocytes synthesize different extracellular
matrix proteins unique to each tissue. In this study, articular cartilage was evaluated
for ER stress, inflammation, autophagy block, proteoglycans, and pro-degradative pro-
cesses and the timing of each process. While stresses that drive mutant-COMP pathology
in growth plate chondrocytes also underlie the articular cartilage pathology, important
unique degradative processes were present.
2. Results
2.1. Mutant-COMP Is Retained in the ER in Adult Articular Chondrocytes
Intracellular retention of mutant-COMP in chondrocytes is a hallmark of
PSACH [21,40,41]. Previously, we have shown that mutant-COMP accumulates in the ER
of growth plate chondrocytes of MT-COMP mice, beginning at E15 [40]. Figure 1, left panel,
shows that human mutant-COMP (red signal) is retained in the ER (green signal) of MT-
COMP chondrocytes (yellow merge) at 4, 8, 12, 16, and 20 weeks (Figure 1F,J,N,R,V). In con-
trast, there is no detectable mutant-COMP in control C57BL\6 mice (Figure 1A,E,I,M,Q,U).
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Figure 1. Retention of human mutant-CO P in ER of T-CO P articular chondrocytes at 4 weeks,
with CHOP expression at 12 weeks. All mice were administered DOX from birth to collection at 2, 4,
8, 12, 16, and 20 weeks. Dotted line marks the edge of articular cartilage. Control and MT-COMP
tibial articular cartilages were immunostained using human COMP-specific antibodies (red) and
protein disulfide isomerase (PDI) (green), an ER marker (A,B,E,F,I,J,M,N,Q,R,U,V). Mutant-COMP
was expressed and retained in the ER of articular chondrocytes of MT-COMP at 4 weeks (F,J,N,R,V)
but not in the controls (A,E,I,M,Q,U). CHOP immunostaining is shown in C,D,G,H,K,L,O,P,S,T,W,X.
CHOP was present in MT-COMP articular chondrocytes at 12, 16, and 20 weeks (P,T,X) and absent in
the controls (C,G,K,O,S,W). (A,B,E,F,I,J,M,N,Q,R,U,V) Bar = 100 µm; (C,D,G,H,K,L,O,P,S,T,W,X)
Bar = 50 µm.
2.2. ER Stress, Inflammation, Matrix Degradation, Autophagy Repression, Senescence, and
Chondrocyte Death Are Present in MT-COMP Articular Chondrocytes
In growth plate chondrocytes, the intracellular accumulation of mutant-COMP stim-
ulates a complex pathological process. This involves activation of the ER stress through
the CHOP pathway, which in turn activates oxidative and inflammatory processes that
exacerbates ER stress, causing an over activation of mTORC1 signaling blocking autophagy,
and ultimately chondrocyte death [43,44]. As shown in Figure 1, CHOP expression in the
MT-COMP articular cartilage is observed at 12, 16, and 20 weeks of age (CHOP panel-P,
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T, X), while it is absent in the controls (C, G, K, O, P, S, W). CHOP is a pro-apoptotic tran-
scription factor that stimulates cell death when ER stress is unresolved [48]. The presence
of CHOP in articular chondrocytes at 12 weeks demonstrates that ER stress is delayed by
8 weeks after the intracellular accumulation of mutant-COMP, which begins at 4 weeks.
Because inflammatory processes involving pro-inflammatory cytokines, IL-1β and
TNFα, play a significant role in the growth plate, these cytokines were investigated in
the articular cartilage (IL-1β data not shown). Shown in Figure 2, TNFα was evident in
the deep zone of articular cartilage at 2 weeks of age and was observed in all zones from
4–20 weeks, compared to little or no signal in the controls, and IL-1β showed a very similar
expression pattern. TNFα and IL-1β promote the synthesis of matrix metalloproteinases
(MMPs), a family of degradative enzymes that cleave collagens and proteoglycans in the
extracellular matrix [49]. MMP13 is synthesized by articular chondrocytes and plays an
important role in the ECM degradation of articular cartilage associated with osteoarthritis
(OA) [49–51]. MMP13 immunostaining was increased in MT-COMP mice with negligi-
ble staining at 8 weeks and a strong signal from 12–20 weeks, compared to the control
articular cartilage, which showed minimal immunostaining (Figure 2). Consistent with
these findings, MMP (2, −3, −9, and −13) activity measured at 12 weeks by MMPSense
was significantly higher in MT-COMP knees (4.26 × 108 ± 6.52 × 107) than in the controls
(3.28 × 108 ± 1.88 × 107) (p < 0.034911) (data not shown). These findings show that joint
degeneration-associated cytokines (TNFα beginning at 4 weeks) and elevated MMP13 im-
munostaining were associated with mutant-COMP accumulation in articular chondrocytes
in MT-COMP mice.
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Figure 2. Degradation, inflammation, and autophagy blockage is increased in MT-COMP articular
cartilage/chondrocytes. All mice were administered DOX from birth to collection at 2, 4, 8, 12, 16, and
20 weeks. Dotted line marks the edge of articular cartilage. Control and MT-COMP tibial articular
cartilage were immunostained (brown) using MMP13 (brown A,B,G,H,M,N,S,T,Y,Z,E’,F’),TNFα
(brown C,D,I,J,O,P,U,V,A’,B’,G’,H’), or pS6 (brown E,F,K,L,Q,R,W,X,C’,D’,I’,J’). Control mice show
no MMP-13 or TNFα signal and minimal pS6. In contrast, the MT-COMP articular chondrocytes
show minimal MMP-13 at 8 weeks, which is increased by 12 weeks; TNFα expression is found in
the deep zone of the articular cartilage at 2 weeks of age and in all three layers at 4, 8, 12, 16, and
20 weeks; pS6 signaling is seen at 12, 16, and 20 weeks. Bar = 100 µm.
Autophagy is repressed in both OA articular chondrocytes [52] and MT-COMP growth
plate chondrocytes [42], therefore, MT-COMP articular chondrocytes were assessed for
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the presence of phosphorylated S6 ribosomal protein (pS6); pS6 is an established read-
out for mTORC1 signaling that regulates synthesis of cellular components and inhibits
autophagy [53]. As shown in Figure 2, pS6 signal was increased in MT-COMP articular
chondrocytes, beginning at 12 weeks, indicating autophagy suppression. In addition to au-
tophagy blockage, articular chondrocyte death increased, beginning at 8 weeks. (Figure 3),
and the loss of these chondrocytes may impact matrix synthesis. Moreover, the increase
in CHOP expression precedes the peak in articular chondrocyte cell death at 16 weeks,
suggesting that CHOP contributes to chondrocyte death in MT-COMP mice (Figure 1
CHOP panel and Figure 3).
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Figure 3. Articular chondrocyte senesc nc and death in MT-COMP mice. All mice were administered
DOX from birth to collection at 2, 4, 8, 12, 16, and 20 weeks. Dotted line marks the edge of articular
cartilage. Control and MT-COMP tibial articular cartilage were immunostained using p16 INK4a
antibodies (brown A,B,E,F,I,J,M,N,Q,R,U,V). p16 INK4a expression is present from 12–20 weeks
(N,R,V). TUNEL staining (green) is shown in C,D,G,H,K,L,O,P,S,T,W,X. The MT-COMP mice show
numerous TUNEL positive articular chondrocytes (L,P,T,X) compared to the controls (C,G,K,O,S,W).
Percent TUNEL positive MT-COMP articular chondrocytes are shown at 8, 12, 16, and 20 weeks.
MT-COMP TUNEL staining is significantly different than the controls * p < 0.05; ** p < 0.005;
*** p < 0.0005 (Y). Sections from the hind limb articular cartilage of at least 10 animals per group were
stained with TUNEL. Bar = 100 µm.
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Senescence is known to play a role in OA joint degeneration [54,55] and was evaluated
in MT-COMP mice using the senescence marker p16 INK4a. As shown in Figure 3, p16
INK4a was observed in MT-COMP articular chondrocytes from 16–20 weeks. (with minimal
staining at 12 weeks.), consistent with the timing of joint degeneration in MT-COMP mice
(Figure 4) [54,55], as well as overlapping with the timing of expression of pS6 (Figure 2).
This suggests that MT-COMP articular chondrocytes experience cellular stress, which
corresponds to senescent articular chondrocytes by 16 weeks, a finding typically associated
with aging and not with relatively young adult mice [56–58].
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Figure 5. Voluntary r ning and gait indices. All mice were administered DOX from birth to collection. Voluntary running
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Stance = the percentage of the stance spent in braking; % Propel Stance = the percentage of the stance spent in propulsion;
Stance Width = the perpendicular distance between the centroids of either set of axial paws during peak stance; Hind Limb
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Alterations of gait can indicate the presence of pain because these alteration are a
natural attempt to reduce stress on limbs associated with pain during ambulation [61]. The
DigiGait system is a treadmill that measures multiple gait parameters and can uncover
subtle changes in gait. Gait was evaluated at 16 weeks with mice running at 30 cm/s
15◦ downhill. As shown in Figure 5B, several gait indices that suggest pain were altered,
including: % brake stance; % propel stance; stance width, and hind limb shared stance
time. MT-COMP mice spent more time braking and less time in the propel phase of stance.
A longer duration in braking stance may indicate more precise control and distribution
of load to reduce peak loading [62]. Importantly, hind limb shared stance time and %
shared stan time were increas d in MT-COMP mice compared to the controls (Figure 5B).
Hind limb shared sta ce time is the amount of time that both limbs are i contact with the
surface. Shared stance time increases with joint pain because distribution of body weight
over both limbs reduces pain [63]. Overall, these measures of gait disturbance suggest that
MT-COMP mice have a wider gait for stability, with care taken when placing paws on the
belt and more time with both hind limbs on the belt to minimize stress on the limbs, which
are all suggestive of pain.
2.4. Joint Degeneration in MT-COMP Mice Is Validated by OA Scoring
OA scoring was used to detect and quantify early degen rative changes in the pro-
teoglycan content of articular cartilage, synovitis, and bone/cartilage. No differences
were detected prior to 16 weeks of age. MT-COMP femur proteoglycan content was less,
and there was a trend toward higher scores for bone/cartilage damage and total score at
16 weeks. (Table 1). A total score of 5.7 was significantly higher in 20 week MT-COMP
mice compared to 2.56 in the controls (with a maximum score of 12). This score included
the cartilage/bone damage score of 0.9 in 20 week MT-COMP mice compared to 0.11 in the
controls and a synovitis score of 1.8 compared to 0.89, respectively (Table 1). These findings
sh that jo nt degeneration occurs in MT-COMP ice by 20 weeks, much earlier than in
the C57BL\6 c ntrol background strain, where it occurs after a year [64], which is again
consistent with early joint degeneration observed in PSACH.
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Table 1. OA score for MT-COMP and control joints.
Age Genotype Pro. Femur Pro. Tibia Bone/Cartilage Synovitis Total
4 weeks
Control 0.78 ± 0.63 0.56 ± 0.50 0.11 ± 0.31 0.33 ± 0.47 1.78 ± 1.13
MT-COMP 0.70 ± 0.64 0.30 ± 0.46 0.40 ± 0.66 1.0 ± 0.89 2.4 ± 1.85
p value - - - - -
Control 0.80 ± 0.60 0.60 ± 0.66 0.10 ± 0.30 0.40 ± 0.66 1.90 ± 1.76
8 weeks MT-COMP 1.3 ± 0.90 0.63 ± 0.14 0.40 ± 0.49 0.60 ± 0.92 2.28 ± 0.11
p value - - - - -
12 weeks
Control 0.77 ± 0.32 0.57 ± 0.26 0.30 ± 0.20 0.52 ± 0.30 1.48 ± 1.06
MT-COM 1.10 ± 0.83 1.20 ± 1.10 0.90 ± 0.94 1.00 ± 0.89 4.20 ± 3.25
p value - - - - -
16 weeks
Control 1.00 ± 0.63 0.80 ± 0.60 0.50 ± 0.50 0.90 ± 0.83 3.20 ± 2.27
MT-COMP 1.60 ± 0.49 1.10 ± 0.54 1.10 ± 0.83 1.50 ± 0.81 5.30 ± 2.19
p value 0.0372 * - 0.0798 - 0.0614
20 weeks
Control 1.00 ± 0.78 0.56 ± 0.65 0.11 ± 0.32 0.89 ± 0.83 2.56 ± 2.15
MT-COMP 1.80 ± 0.87 1.20 ± 0.60 0.90 ± 0.70 1.80 ± 0.60 5.70 ± 2.14
p value 0.0683 0.0542 0.0091 ** 0.0218 * 0.0133 *
Each category is: Pro. Femur = proteoglycan content in femur articular cartilage; Pro. Tibia = proteoglycan content
in tibial articular cartilage. Bone/Cartilage and Synovitis are scored from 0–3, with a maximum total of 12. The
average in each category ± standard deviation is presented, with significant p-values, * p < 0.05 and ** p < 0.005,
in bold text, and trending p-values < 0.10 are also shown.
2.5. Prevention of Joint Degeneration in MT-COMP Mice with Resveratrol Treatment or Ablation
of CHOP
Previously, we have shown that resveratrol treatment reduces ER stress by promoting
autophagy that clears accumulated mutant-COMP from the ER in growth plate chon-
drocytes of MT-COMP mice [65]. Resveratrol relieved the ER protein accumulation and
reduced chondrocyte death, restoring proliferation and supporting limb growth in juvenile
MT-COMP mice [65]. Based on these results, resveratrol was administered to determine
whether it could prevent and/or reduce joint degeneration in MT-COMP mice. As shown
in Figure 6, resveratrol treatment from birth to 20 weeks dramatically reduced the loss of
proteoglycans in the articular cartilage of adult mice (Figure 6A–D) and decreases total OA
score from 5.70± 2.14 (MT-COMP) to 1.3± 1.55 (MT-COMP +resveratrol *** p < 0.0005) sim-
ilar to controls 2.56 ± 2.15 (data not shown). Importantly, resveratrol treatment prevented
the accumulation of mutant-COMP in the ER of articular chondrocytes (Figure 6E–H)
reduced ER stress (Figure 6M–P), and substantially reduced articular chondrocyte death
(Figure 6I–L) and TNFα inflammation (Figure 6Q–T). Consistent with normalization of
proteoglycans in the articular cartilage of MT-COMP mice treated with resveratrol, MMP-13
signal was markedly reduced (Figure 6Y–B’). Resveratrol reduced multiple mutant-COMP
pathologies, including inflammation and ER stress, and importantly block autophagy,
which allows chondrocytes to clear misfolded protein and prevent cell death. Similarly,
genetic ablation of CHOP was used to interrupt the ER stress signaling pathway that
breaks down the pathological loop between ER stress, inflammation, and oxidative stress.
MT-COMP/CHOP−/− articular cartilage at 20 weeks was healthy (Figure 6D) and MMP-
13 was minimal (Figure 6B’). The loss of CHOP considerably reduced accumulation of
mutant-COMP in articular chondrocytes (Figure 6H) and the number of TUNEL positive
chondrocytes (Figure 6L).
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Figure 6. Articular cartilage of MT-COMP mice is preserved with resveratrol treatment or CHOP
ablation. DOX was administered to all mice and resveratrol treatment to one group of MT-COMP mice
(C,G,K,O,S,W,A’,E’) from birth to 20 eeks. Dotted line marks the edge of articular cartilage. All articular
cartilages were stained with safranin O (red/pink A–D) or immunostained using human COMP-specific
antibodies (red, E–H) and protein disulfide isomerase (PDI), an ER marker (green, E–H), or TUNEL (green,
I–L) and DAPI (blue uclei, I–L), CH P (green, M–P ER stress marker) and DAPI (blue, nuclei M–P),
TNFα (brown Q–T), pS6 (brown U–X), MMP13 (brown Y–B’), or p16 INK4a (brown C’–F’). Safranin O
staining shows that MT-COMP articular cartilage has l ss proteoglycans (B) compared to the control
(A), and both resveratrol treated and ablation of CHOP normalizes proteoglycan content (C,D). TUNEL
positive MT-COMP articular chondrocytes in (J) are more numerous than in the control (I), resveratrol
treated (K), or MT-COMP/CHOP−/− (L). TNFα inflammation is decreased in resveratrol treated (S), or
MT-COMP/CHOP−/− (T) articular chondrocytes compared to MT-COMP (R). mTORC1 signal activity
(pS6) is detected in MT-COMP mice (V) compared to the controls (U), resveratrol treated MT-COMP (W),
or MT-COMP/CHOP−/− (X) mice. Increased MMP-13 is present in MT-COMP (Z) articular cartilage
compared to the controls (Y), resveratrol treated (A’), or MT-COMP/CHOP−/− (B’) mice. Senescent
articular chondrocytes (p16 INK4a) were observed in MT-COMP mice (D’), whereas a minimal p16 INK4a
signal is seen in the controls (C’), resveratrol treated (E’), or MT-COMP/CHOP−/− (F’). Bar = 100 µm.
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3. Discussion
Using our MT-COMP mouse model of PSACH, we found that retention of mutant-
COMP in the ER of articular chondrocytes induces and drives a CHOP-dependent ER
stress pathologic loop involving multiple inflammatory processes. Persistent inflammation
drives autophagy blockage and, ultimately, chondrocyte death. The presence of senescence
and a degenerative environment likely adversely impacts surrounding tissue, including
synovium and subchondral bone. The results of this study show that MT-COMP mice
undergo premature joint degeneration similar to the premature joint degeneration in
PSACH, providing a model system for studying nonsurgical joint sparing therapeutics.
Multiple cellular stresses were observed in MT-COMP articular chondrocytes, includ-
ing ER stress (CHOP), inflammation (TNFα), ECM degradative enzymes (MMP-13), block
of autophagy (pS6), and senescence (p16 INK4a). Importantly, these stresses were not
observed in MT-COMP mice in the absence of DOX (Supplemental Figure S1). TNFα stim-
ulates excessive mTORC1 signaling (indicated by pS6), consequently blocking autophagy
and preventing mutant-COMP from being cleared from the ER through macroautophagy
(referred to as autophagy). The autophagy blockade means that the ER cannot be cleared
and the pathology is perpetuated without therapeutic intervention. Moreover, elevated
mTORC1 signaling maintains protein synthesis, and this counteracts repression of transla-
tion mediated by the unfolded protein response to assist with clearance of the ER.
Aging and/or cellular stress stimulates senescence [57,66], and senescent articular chon-
drocytes were observed in the articular cartilage of MT-COMP mice at 16 weeks. The multiple
chronic stresses that occur in MT-COMP articular chondrocytes likely stimulate senescence
similar to that observed in OA [56]. Based on our ER-stress mechanistic model, we expect that
inflammation, ER stress, MMP expression, autophagy blockage, senescence, and chondrocyte
death will each contribute to articular cartilage erosion [42,43,45,67–70]. Unique to the MT-
COMP articular chondrocytes is the presence of the well-known degradative enzyme MMP-13
and senescence, both of which are associated with OA in humans and animal models [56,71].
These findings suggest that mutant-COMP joint degeneration shares some cellular pathology
with OA.
The timing of mutant-COMP joint degeneration is distinct from the mutant-COMP
growth plate pathology. In articular chondrocytes, mutant-COMP retention and inflam-
mation start at 4 weeks, and ER stress, blockage of autophagy, and chondrocyte death
are seen between 8 and 12 weeks (summarized in Table 2). In contrast, mutant-COMP
retention in the growth plate is seen prenatally with inflammation starting postnatally at
2 weeks, peaking between 3–4 weeks, and chondrocyte death is significantly increased
by 4 weeks [39,47,48]. These tissues serve very different functions, with growth plate
driving linear growth, from birth to 10 weeks, and the articular cartilage needed to cushion
mechanical forces that are not required in early life (birth to 3 weeks) when ambulation
is limited. Articular cartilages primarily absorb and distribute mechanical forces so these
mechanical stresses are not transmitted to the bone. In contrast, the growth plate is a niche
for the maturation of growth plate chondrocytes that eventually generate copious amounts
of ECM that will be calcified and turned into bone. These functional differences may
explain the novel mutant-COMP articular chondrocyte pathology of matrix degradation,
senescence, and premature joint degeneration in MT-COMP mice.
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Table 2. Timing of articular chondrocyte pathology.
Mutant-COMP Pathology 2 4 8 12 16 20 Weeks
Mutant-COMP intracellular retention X X X X X
Proteoglycan loss (Safranin O) X X
ER stress (CHOP) X X X
Chondrocyte death (TUNEL) X X X X
Inflammation (TNFα) * X X X X X
Autophagy block (pS6) * X X X
Enzymatic degradation (MMP-13) * X X X
Senescent chondrocytes (p16 INK4a) * X X
DOX administered from birth to collection at 2, 4, 8, 12, 16, and 20 weeks. Mutant-COMP intracellular retention,
proteoglycan loss, ER stress, TNFα inflammation, autophagy block, senescent chondrocytes, degradation enzyme
MMP-13, and chondrocyte death are present (X) and begin between 4–16 weeks. * = some immunosignal.
MT-COMP mice undergo premature joint degeneration far earlier than the background
strain (C57BL\6) that develop joint degeneration beginning at 1 year of age. While there
is limited information about the temporal development of joint degeneration in PSACH,
natural history studies show that there is premature joint degeneration in PSACH, starting
in mid- to late teenage years [32]. Based on this information, we posit that the MT-COMP
mouse is a good model system for understanding the PSACH/mutant-COMP pathologies.
The essential role of CHOP in the mutant-COMP joint degenerative process is illus-
trated by the alleviation of articular chondrocyte stress in MT-COMP/CHOP−/−mice.
Notably, the MT-COMP/CHOP−/−mice still express mutant-COMP, but in the absence of
CHOP the mutant-COMP pathology is diminished. Similarly, resveratrol treatment from
birth to 20 weeks dampens the mutant-COMP pathologies of ER stress (CHOP), inflam-
mation (TNFα), block of autophagy (pS6), and senescence (p16 INK4a). This reduction of
ER stress and inflammation interrupts the pathological loop between ER, oxidative stress,
and inflammation. Moreover, resveratrol restoration of autophagy allows clearance of
mutant-COMP from the ER of articular chondrocytes. These proof-of-principle findings
show that the articular cartilage of MT-COMP mice can be preserved if intervention occurs
prior to a point of no return and opens new therapeutic avenues for PSACH.
4. Materials and Methods
4.1. Bigenic Mice
The MT-COMP mice used in these and previously described experiments contain the
pTRE-COMP (coding sequence of human COMP + FLAG tag driven by the tetracycline
responsive element promoter) and pTET-On-Col II (rtTA coding sequence driven by a
type II collagen promoter) [39,47,53]. DOX (500 ng/mL) was administered to mice at birth,
through mother’s milk, to collection, in their drinking water. This study complied with the
Guide for the Care and Use of Laboratory Animals, eighth edition (ISBN-10, 0-309-15396-4)
and was approved by the Animal Welfare Committee at the University of Texas Medical
School at Houston and complies with NIH guidelines.
4.2. Generation of CHOP Null Bigenic Mice
CHOP null mice were procured from Jackson Laboratories and mated with MT-COMP
bigenic mice to obtain a strain expressing MT-COMP in a CHOP null background (MT-
COMP/CHOP−/−), as used in previous experiments [43,48]. Genotypes of the CHOP null
mice were verified using CHOP-specific primers [48].
4.3. Immunohistochemistry
Hind limbs from male and female MT-COMP and C57BL\6 control mice were collected
and articular cartilage analyzed, as previously described [40,42,43]. Briefly, the limbs were
fixed in 95% ethanol followed by decalcification in immunocal (StatLab McKinney, TX,
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USA) for 1 week, and pepsin (1 mg/mL in 0.1N HCl) was used for antigen retrieval
for immunostaining with antibodies for human COMP (Thermofisher, Waltham, MA,
USA; MA1-20221, 1:100), CHOP (Santa Cruz Dallas, TX, USA; SC-575; 1:100), interleukin
1 (IL-1) (Abcam Cambridge, United Kingdom; ab7632, 1:200), tumor necrosis factor α
(TNFα) (Abcam Cambridge, United Kingdom; ab6671, 1:200), PDI (Santa Cruz Dallas, TX,
USA; SC-20132, 1:100), p16 INK4a—(Abcam, Cambridge, UK; ab189034, 1:200), pS6 (Cell
Signaling Technology 2215S rabbit polyclonal, 1:200), and MMP-13 (Abcam Cambridge,
United Kingdom: ab39012, 1:50). Species specific biotinylated secondary antibodies were
used for 1 hr at RT. Sagittal sections of the same thickness (5 um) were then washed
and incubated with streptavidin horseradish peroxidase (HRP), and DAB was used as
chromogen. The sections were dehydrated and mounted with cytoseal 60 (Thermofisher,
Waltham, MA, USA) and then visualized under a BX51 inverted microscope (Olympus
America, Center Valley, PA, USA). Limbs were fixed in 10% wt/vol formalin for terminal
deoxynucleotidyl transferase–mediated deoxyuridine triphosphate-biotin nick end labeling
(TUNEL) staining. For proteoglycan stains, samples were deparaffinized and hydrated
in distilled water and stained with safranin-O (Spectrum Chemical, New Brunswick, NJ,
USA, 477-73-6) according to the manufacturer’s protocol. Immunostaining was performed
on 10 animals in each group.
4.4. Gait Analysis
Gait of male mice was analyzed using a DigiGait treadmill system (Mouse Specifics
Inc., Boston, MA, USA) following the protocol described for collagen-induced OA [40].
Previously, it has been shown that running during gait analysis was necessary to uncover
subtle changes in ambulatory function that are associated with OA [63]. Briefly, video
camera images of mice running through a transparent belt were captured and analyzed. At
least 3 sec of downhill 15◦ running continuous strides were used to calculate and measure
gait parameters with DigiGait software version 12. Mice were run for 30 cm/sec and
gait analysis was performed in the animal behavioral testing room, and assessments were
performed by software so that blinding was not necessary. DigiGait recommends 3 mice per
group to measure ethanol induced ataxia or running speed (https://mousespecifics.com/
digitgait-protocols/, accessed on 22 May 2021). Based on this information, 5 mice/group
were analyzed because OA gait dysfunction is subtler to detect compared to ethanol
induced ataxia. ANOVA analysis was performed, followed by pairwise comparisons
with Kruskal–Wallis and post hoc Dunn’s analysis. All mice were moved to the behavior
room at 8:00 a.m. and DigiGait analysis occurred between 9:00 a.m.–12:30 p.m. Due to the
dwarfing phenotype associated with expression of mutant-COMP in mice [45–47], only gait
parameters not influenced by size were considered. Changes in bone shape (metaphyseal
flaring) [45] cannot be accounted for in gait analysis, and this a limitation of this study.
4.5. OA Scoring
OA scoring was performed on 10 different 5 um sagittal sections (from individual
mice). To ensure sections were from the same area of the joint; only sections that contained
both menisci were scored. While OARSI scoring covers a wide range of OA pathology,
in this study, OA scoring was modified to optimize evaluation of early OA pathology.
Four areas, synovium, bone/cartilage, tibial and femoral articular cartilage, were scored
from 0 to 3 on each safranin-O stained section. A score of 0 indicated normal or no dam-
age, 1 = mild damage, 2 = moderate damage, and 3 = denotes severe damage. Synovitis,
bone/cartilage damage, and proteoglycan of the tibia and femur were scored individually,
and all scores were summed with maximal damage being associated with a score of 12.
Synovitis was defined as: mild—increase in thickness of synovial lining and increase in
stromal area, moderate—increase in stromal density, or severe—thickening of synovial
lining with further increase of stromal cellular density. Bone/cartilage damage was defined
as: normal—surface was smooth, mild—minor erosion of the surface, moderate—presence
of remodeling with minor erosion, or severe—major erosion. Proteoglycans of the articular
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cartilage of the tibia and femur was classified as: normal—if staining was even through
to the subchondral bone, mild—when staining was thinned, moderate—thinning of pro-
teoglycan stained layer and absence of staining in some areas, or severe—widespread
loss of proteoglycan staining. Ten mice per experimental group were used for each time
point, providing 80–90% power to detect a minimal difference of 2 or 3 units. All scoring
was performed blindly. Section depth, thickness, fixation, and decalcification conditions
were all identical for all limbs analyzed. The Kruskal–Wallis test was used to evaluate
distribution of OA scores across 6 experiment groups, with Post-hoc Dunn’s test comparing
MT-COMP to controls.
4.6. MMPSense
Mice were treated with depilatory cream to remove hair prior to imaging. MMP 680
reagent was injected into the tail vein, and animals were imaged 24 h later, as per manu-
facturer’s instructions, along with an uninjected control (UIC). Males were imaged on an
IVIS Spectrum In Vivo Imaging System (PerkinElmer; Waltham, MA, USA) (https://www.
perkinelmer.com/lab-solutions/resources/docs/APP_Protocol_MMPSense%20680.pdf, ac-
cessed on 22 May 2021). MMP 680 is an optically silent substrate that fluoresces when
cleaved by MMP-2, -3, -9, and -13. MMPSense signal was assessed blindly by positioning
a circle of a standard size around the knee (in all samples), and radiance efficiency was
generated from IVIS software. Six mice were included per group, and the system had the
power to detect a difference of 30% or greater. Mann–Whitney U test was used to evaluate
MMP activity in control and MT-COMP mice.
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